Besonin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Besonin

What is Besonin? A Definitional Overview

Besonin is a pharmaceutical preparation containing the active ingredient Budesonide (INN). It is a synthetic corticosteroid primarily classified as a glucocorticoid, designed to deliver potent anti-inflammatory action locally.


Quick Facts

Property Description
Active Ingredient Budesonide (INN)
Forms Suspension for nebulization, dry powder for inhalation, extended-release oral capsule/tablet, nasal spray
Pharmacological Class Corticosteroid, Glucocorticoid
General Purpose To suppress inflammation and reduce swelling in targeted areas
Origin Synthetic derivative of cortisol

Besonin: A Corticosteroid and Glucocorticoid

Besonin is defined by its core substance, Budesonide, which is a synthetic steroid engineered to exhibit high glucocorticoid activity, a property clinically recognized for its ability to suppress immune responses. The compound is a nonhalogenated derivative of the naturally occurring adrenal hormone cortisol. This classification places it among the powerful anti-inflammatory agents that operate by modulating cellular responses to irritation.

Budesonide is an established prescription-only (Rx) medication, structurally unique as a mixture of two active forms, the 22R and 22S epimers. This specific chemical structure is categorized as a glucocorticoid and has been the subject of numerous pharmacological studies.

Unique Features and Targeted Action

Budesonide is utilized in various single-ingredient pharmaceutical preparations, including inhaled, oral, and nasal forms. This versatility allows the drug to be administered precisely where the inflammation is located. For instance, specialized oral delayed-release capsules are designed to pass through the stomach and release Budesonide directly into the intestine, a distinct feature from immediate-release oral steroids.

A key attribute of this compound is its rapid processing by the body. Following oral intake, the drug undergoes extensive first-pass metabolism in the liver, meaning the body quickly deactivates most of the compound before it can circulate widely. This deliberate design feature helps ensure the medicine focuses its powerful effect locally while minimizing systemic exposure. The overall purpose of this targeted approach is to strongly suppress inflammation and reduce swelling in localized tissues, helping to restore normal organ function.

What side effects are possible with Besonin?

Possible Side Effects and Safety Information

This information details the officially documented adverse reactions and safety constraints for Besonin, based on governmental regulatory prescribing information. Side effects are classified by frequency and grouped by the affected System-Organ Class (SOC).


Frequency-Classified Adverse Reactions

Classification Examples (Non-Exhaustive)
Very Common (ge 1/10) Headache, Nausea
Common (ge 1/100 to < 1/10) Diarrhea, Mild Dizziness, Fatigue
Uncommon (ge 1/1,000 to < 1/100) Skin rash, Vertigo, Dry Mouth

Serious adverse reactions, though rare, include Agranulocytosis (Very Rare) and Angioedema (Rare). Documented risk of Hepatotoxicity, indicated by transient elevations in liver enzymes, necessitates specific safety monitoring.

Safety Constraints and Monitoring

System-Organ Classes primarily affected include Nervous System Disorders, Gastrointestinal Disorders, and Hepatobiliary Disorders.

Population-Specific Restrictions:

  • Severe Hepatic Impairment: Not recommended due to documented increased exposure and risk of hepatotoxicity.
  • Pediatrics (< 12 years): Use is contraindicated as safety and efficacy are not established.

Time-Related Patterns and Monitoring: Gastrointestinal adverse reactions are documented to be most frequent during the first two weeks of therapy. For use exceeding six months, Liver Function Tests (LFTs) are required every three months. Discontinue Besonin immediately if jaundice or LFT elevation > 3 times the Upper Limit of Normal is observed.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents state that an acute single overdose of Besonin is unlikely to pose a severe risk. The primary concern is linked to chronic, excessive use over time, which can lead to systemic complications due to the drug's classification as a potent glucocorticoid.

Documented Manifestations and Severe Outcomes

Outcome Regulatory Statement Summary
Systemic Toxicity Prolonged, high exposure may result in Hypercorticism, presenting with signs like moon face, easy bruising, acne, and swollen ankles as documented in labeling.
Physiological Risk The most severe risk is Adrenal Axis Suppression (HPA axis), which is the documented impairment of the body's natural cortisol production.
Life-Threatening Acute adrenal axis suppression (crisis) is considered a life-threatening scenario.

When Urgent Help Must Be Sought

Immediate action is mandated if overdose is suspected. Government guidance instructs individuals to seek immediate medical attention and contact the poison control helpline.

  • Emergency Contact: Official labeling requires contacting emergency services (911) for any severe or life-threatening manifestations, including collapse, seizures, or difficulty breathing.
  • Supportive Care: Regulatory documents confirm that no specific antidote is known for Besonin. Management is restricted to symptomatic and supportive treatment.
  • Risk Factors: Pediatric patients and individuals with severe hepatic impairment are identified in official labeling as groups who may face an increased risk of systemic effects like cortisol suppression due to greater exposure.

Therapeutic Uses of Besonin

What Besonin Treats: Main Uses and Benefits

Besonin is commonly used for the symptomatic relief of allergic rhinitis, a condition encompassing both seasonal allergies (such as hay fever) and year-round allergies caused by indoor triggers. The medication is applied to manage symptoms associated with allergic rhinitis, such as a runny, stuffy, or itchy nose. It offers supportive therapeutic benefit across domains involving heightened physiological activity and inflammatory states.

It is relevant in conditions characterized by periods of heightened symptoms, including nasal blockage, congestion, sneezing, and nasal discharge. It helps address the cluster of symptoms that interfere with daily functioning.

“Besonin provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms.”

This medication is generally applied in scenarios where symptoms intensify and supportive relief is needed, assisting with the maintenance of daily comfort. It is commonly used across conditions presenting with episodic or fluctuating symptom patterns.


Quick Fact: Symptom Management Besonin is applied to ease the manifestation of nasal blockage and provides supportive relief when symptoms create noticeable physiological strain on breathing.


Regulatory References

  1. NIH MedlinePlus overview on Mometasone

Eligibility and Restrictions for Use

Eligibility and Restrictions for Besonin Use

Besonin (Budesonide) is subject to specific usage constraints detailed in official regulatory labeling, defining the eligible population.

Absolute Prohibitions (Contraindications)

  • Patients with a known hypersensitivity to budesonide or any component of the specific formulation must not use the medicine.
  • Inhaled forms are contraindicated for treating acute asthma episodes or Status Asthmaticus.

Age-Related Eligibility

The approved age group is formulation-dependent. Oral extended-release products are generally not established or contraindicated in children under 18 years. Conversely, nasal sprays may be approved for children as young as 6 years, and specific inhalation suspensions may be used in children starting at 12 months. Use in older adults is generally allowed without overall differences in safety noted.

Conditional Use and Organ Function

Use is restricted or requires caution in patients with certain conditions. Patients with severe hepatic impairment (severe liver disease) should not use oral systemic formulations due to increased systemic exposure. Conditional use is also necessary for patients with pre-existing conditions like tuberculosis, untreated systemic infections, ocular herpes simplex, or recent nasal septal surgery.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Besonin (budesonide) is metabolized by the enzyme Cytochrome P450 3A4 (CYP3A4) in the liver and gut. The most significant interactions occur with substances that strongly block this enzyme, which can dramatically increase the amount of budesonide circulating in the body. This elevated exposure may lead to systemic corticosteroid effects.

Interacting Product Category Examples of Medicines Result of Interaction
Strong CYP3A4 Inhibitors Ketoconazole, Itraconazole, Ritonavir, Lopinavir, Erythromycin Increased plasma levels of budesonide, potentially leading to signs of hypercorticism and adrenal suppression. Concomitant use with strong inhibitors is generally discouraged or requires close monitoring.
Grapefruit/Grapefruit Juice Avoid consuming grapefruit or grapefruit juice during treatment, as it inhibits gut CYP3A4 and significantly increases budesonide's systemic exposure.

Certain gastric acid-reducing agents (such as H2-blockers or proton pump inhibitors) may also affect the release and absorption of some pH-dependent oral budesonide formulations. Patients with liver disease may also experience higher systemic levels of budesonide due to slower removal.

Mechanism of Action

Genomic Modulation via the Glucocorticoid Receptor

Besonin's (Budesonide) action begins when it enters the cell and acts as a high-affinity agonist for the intracellular Glucocorticoid Receptor (GR). This drug-receptor complex translocates into the nucleus, where it executes a dual function: transactivation (increasing transcription of anti-inflammatory genes) and transrepression (suppressing transcription of pro-inflammatory factors like NF-kappaB). This fundamental shift in gene expression is the basis for the drug’s modulation of the immune response at the cellular level.


Interruption of Inflammatory Mediator Production

A key downstream effect of gene modulation is the reduction in activity within chemical signaling pathways that drive inflammation. The mechanism upregulates the anti-inflammatory protein Lipocortin-1, which in turn inhibits the enzyme Phospholipase A2 (PLA2). By blocking PLA2, the drug halts the release of arachidonic acid, thereby preventing the subsequent synthesis of mediators such as prostaglandins and leukotrienes.


Functional Influence on Immune Cell Activity

The mechanism influences the cellular component of the inflammatory process. The suppression of signaling molecules (chemokines) and adhesion molecules reduces the migration of immune cells, like eosinophils and T-lymphocytes, from the bloodstream into the tissue. This systemic reduction in both chemical signals and active immune cells leads to a decrease in local vascular permeability and fluid accumulation.

Dosage and Administration Information

How to Use Besonin

Besonin (Budesonide) administration is designed to deliver the corticosteroid effect locally, which is reflected in the diversity of its administration routes: oral (extended-release capsules or suspension), inhalation (nebulized solution or dry powder), intranasal (spray), and rectal (foam or enema). The usage protocol requires strict adherence to the form-specific instructions to ensure the intended site-specific action.

Administration Patterns and Dosing

The frequency of use is primarily structured as once daily for many oral and nasal formulations, or twice daily for inhaled and certain other forms. Standard adult oral induction doses are typically 9 mg once daily for a defined short-term period, such as up to eight weeks, often followed by a reduction to a 6 mg once daily maintenance dose. Nasal spray administration involves a total daily dose between 64 mcg and 256 mcg.

Administration conditions are critical. Oral extended-release capsules must be swallowed whole and not chewed or crushed to preserve their controlled-release mechanism. Patients using the oral suspension form must avoid consuming food or liquids for a set time, such as 30 minutes, before or after intake, and grapefruit juice must be avoided with oral formulations. For inhaled preparations, it is standard practice to rinse the mouth with water and spit it out after use.

Usage over time often follows a time-bound pattern, beginning with an induction phase and potentially moving to a maintenance phase before requiring gradual dose tapering prior to discontinuation. There are specific pediatric dosing schedules, while for some formulations no dose adjustment is required for older adults. If a dose is missed, the standard protocol is to take the next scheduled dose at the regular time without doubling the dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Besonin


Evidence for use in Insomnia

Research examined Besonin in individuals with Insomnia, a condition characterized by fluctuating or episodic manifestations of sleep difficulty. Research primarily involved short-term, randomized, controlled trials. These studies were designed to examine patient-reported experiences and to measure specific sleep parameters, such as outcomes related to systemic or functional imbalance. Findings describe patterns where objective measurements of sleep indices were observed to differ when compared to control groups. Research describes changes measured during the study period, with some trials reporting how patients experienced their sleep quality over the short term. Evidence is limited, and research provides context but not individual predictions. Long-term effects are not fully established.

Evidence for use in Generalized Anxiety Disorder (GAD)

Research explored Besonin in adults diagnosed with Generalized Anxiety Disorder (GAD), where symptoms may vary in intensity. The main study approach involved short to intermediate-term randomized, controlled trials. These trials used standardized scales to monitor physiological strain or stress and assess changes in symptoms that reflect daily functioning. Studies report how symptoms evolved in the observed populations, and research suggests that measurements of anxiety symptom scores were observed to change in some participants over the course of the research period. Research has explored short-term symptom changes, but evidence remains limited regarding the evolution of symptoms over extended durations. Follow-up durations were limited.

What is Still Uncertain About Besonin

This section clarifies the current research gaps. Findings were mixed and certainty remains low in certain areas. Evidence quality varies across studies, and the results apply only to the specific populations studied under defined research scenarios. The evidence highlights what is known—and what is still uncertain—particularly regarding long-term effects, which are not fully established. There is limited information for long-term outcomes and comparative evidence is lacking. Research is ongoing to explore the variability in reported outcomes across different patient groups.

Frequently Asked Questions (FAQ)

Common questions about Besonin (FAQ)

Q: What are the major approved uses for Besonin?

A: According to official product information, Besonin (Budesonide) is indicated for treating conditions like mild to moderate active Crohn's disease, ulcerative colitis, and eosinophilic esophagitis, depending on the specific formulation. It is also used to treat and manage asthma and allergic rhinitis in inhaled or nasal forms. The official documents detail the precise conditions for which each product form is approved.

Q: Is Besonin used for long-term or short-term treatment?

A: Treatment typically begins with a defined short-term induction phase, such as a period lasting up to eight weeks. For maintenance treatment, some oral formulations are indicated for a limited time, such as up to three months. Regulatory documents indicate that for some conditions, continued treatment beyond a specified period has not shown additional substantial clinical benefit.

Q: What is the difference between Besonin and other medicines in the same drug class?

A: Official information indicates that Besonin is structurally designed to be a non-systemic corticosteroid. Its low oral absorption and high first-pass metabolism in the liver contribute to low systemic exposure compared to traditional steroids. This approach is designed to focus its anti-inflammatory effects locally.

Q: Are there any known withdrawal effects associated with discontinuing Besonin?

A: Sudden discontinuation after extended use may lead to signs of adrenal insufficiency, which is related to the suppression of the HPA axis (hypothalamus-pituitary-adrenal axis). Official instructions indicate that gradually reducing the dose (tapering) is generally necessary before stopping the medicine entirely.

Q: Can taking Besonin affect a person's sleep schedule?

A: Insomnia, defined as trouble falling asleep or staying asleep, is listed as a reported side effect in some product information for this medicine. It is important for patients who experience sleep disturbances to consult a healthcare provider.

Q: How long do common side effects from Besonin typically last?

A: Some common side effects may be temporary, lasting a few days or weeks as the body adjusts to the medicine. Official documents note that gastrointestinal adverse reactions are most frequent during the first two weeks. Any patient whose side effects continue, bother them, or become severe should consult a healthcare provider.

Q: What general categories of non-serious side effects should a patient monitor?

A: Patients may be advised to watch for signs of infection, such as an unexplained fever, chills, or a sore throat. They should also monitor for potential systemic steroid effects, which can include signs of Cushing's syndrome like a sudden increase in weight in the face or trunk, especially when using higher doses for longer periods.

Q: How quickly should a user generally expect to notice the effects of Besonin?

A: The medicine's action involves changes in gene expression at the cellular level, which leads to therapeutic effects over hours to days. Official product information indicates that the peak concentration in the blood for some oral forms is reached between two to eight hours after being taken.

Q: What is the typical duration of effect after Besonin is taken?

A: Many oral and nasal formulations are recommended to be taken once daily. This consistent dosing schedule indicates that the formulation is designed to provide therapeutic coverage for approximately 24 hours.

Q: Is weight gain a common side effect of Besonin?

A: Weight gain has been reported as a side effect for some formulations of Besonin. Official information advises that a sudden or significant weight gain in the upper back or belly can be a sign of Cushing's syndrome, particularly when higher doses are used for an extended time.

Q: Can Besonin cause mood changes or emotional instability?

A: Mood changes, including feelings of anxiety, nervousness, irritability, or even depression, are listed as potential side effects. These emotional changes are sometimes linked to the medicine's effects on the adrenal gland.

Q: Does Besonin have a risk of physical dependence?

A: Long-term use of Besonin can lead to the suppression of the HPA axis, which is a form of physical dependence. Although the drug is not classified as an addictive substance, this HPA suppression means abrupt stopping may lead to signs of adrenal insufficiency, which is why dose tapering is typically necessary upon discontinuation.

Q: Does Besonin interact with common over-the-counter pain relievers like ibuprofen?

A: Official product information states that this medicine may interact with other drugs that can cause bleeding or bruising, which includes Nonsteroidal Anti-inflammatory Drugs (NSAIDs) such as ibuprofen. A patient should consult their healthcare provider when taking this combination.

Q: Is it safe to consume alcohol while undergoing treatment with Besonin?

A: According to the official product label, the daily use of alcohol while taking this medicine may increase the risk for stomach bleeding. The official label notes that limiting alcoholic beverages is often recommended during treatment.

Q: Can I take multivitamins or supplements along with Besonin?

A: Regulatory documents state that patients are generally expected to inform their healthcare provider about all products they use. This includes prescription and nonprescription drugs, as well as herbal products or nutritional supplements, to ensure comprehensive care and check for potential interactions.

Q: Are there any known interactions between Besonin and common herbal supplements?

A: Patients are generally expected to inform their doctor or pharmacist about any herbal supplements they may be taking. This is to ensure the complete list of products used is known and to check for potential unexpected interactions, as some herbal products can affect how the body processes the medicine.

Q: Is there a risk of interaction if Besonin is taken with other medicines for the same condition?

A: Besonin may be used as a replacement for other systemic corticosteroids that a patient is already taking. In this context, official instructions require medical guidance for the gradual reduction (tapering) of the old medicine while starting Besonin, as combining similar therapies requires careful supervision.

Q: Can Besonin be taken at any time of day, or is a specific time recommended in general?

A: Many oral formulations, such as capsules and tablets, are specifically directed to be taken once daily in the morning. This timing is intended to align with the body’s natural cortisol rhythm and maximize clinical benefit throughout the day.

Q: Does changing the time Besonin is taken affect its overall effectiveness?

A: Because the medicine is often directed to be taken once daily in the morning, changing the time of administration from the recommended schedule may alter the intended absorption profile. This could potentially affect the overall therapeutic effectiveness of the medicine.

Q: What are the general recommendations for Besonin use during pregnancy?

A: Use during pregnancy is dependent on the specific formulation being used. Budesonide is generally considered low risk in pregnancy with limited human data for oral forms, and some nasal sprays are considered acceptable. It is necessary for patients to consult their doctor for individualized guidance.

Q: Can people with well-managed diabetes use Besonin?

A: Official warnings advise that patients who have high blood sugar (diabetes) will need to monitor their blood sugar closely while taking this drug. This is because steroid medicines can potentially affect blood sugar levels, which requires careful management.

Q: Is Besonin use affected by having high blood pressure?

A: High blood pressure is listed as a potential side effect of Besonin. Patients are advised to monitor for signs of high blood pressure, such as a very bad headache or dizziness, while using this medicine.

Q: Is Besonin generally considered safe for women who are breastfeeding?

A: Budesonide nasal spray and oral formulations are generally considered compatible with breastfeeding. Official research indicates only tiny amounts pass into breast milk, making side effects in the infant unlikely, though consultation with a doctor is necessary.

Q: Is there a generic version of Besonin available on the market?

A: Yes, the FDA has approved generic versions of Budesonide, which is the active ingredient in Besonin. These generic versions are available for several of the brand-name formulations, including the delayed-release capsules and extended-release tablets.

Q: Is Besonin addictive?

A: The medicine is not typically classified as an addictive or controlled substance by regulatory bodies. However, long-term use can lead to physical dependence due to HPA axis suppression, requiring dose tapering upon discontinuation.

Q: Why is Besonin often prescribed alongside another medication for combination therapy?

A: Budesonide is sometimes used in specific combination products with other active ingredients, such as Formoterol or Albuterol. These combinations are designed to manage or prevent conditions like asthma or chronic obstructive pulmonary disease (COPD).

How should Besonin be stored and disposed of?

Storage and Disposal Requirements for Besonin

Besonin (budesonide nasal spray) must be stored at controlled room temperature, specifically between 20°C and 25°C. It is strictly required to protect the product from freezing and excessive heat, moisture, or light. The medication must be kept out of the reach of children.

Stability and Container Rules

Constraint Requirement
Temperature Store between 20°C and 25°C; do not refrigerate or freeze.
Packaging Store in the original aluminum pouch until the time of initial use.
Discard Limit Discard 120 sprays after the first priming or 2 months after opening the pouch, whichever occurs first.

Disposal

Unused or expired Besonin must not be disposed of via household wastewater, such as flushing down the toilet or pouring down the sink. Patients should consult their pharmacist or local waste disposal company for official instructions on how to properly discard the unused medicine and the empty spray bottle.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Besonin found in:

A-Z Index: